2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
20
Glioblastoma
12
Neoplasms
10
Breast Neoplasms
10
Pancreatic Neoplasms
9
Glioma
8
Carcinoma, Non-Small-Cell Lung
8
Ovarian Neoplasms
7
Triple Negative Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Prostatic Neoplasms
5
Colonic Neoplasms
5
Urinary Bladder Neoplasms
4
Sarcoma
4
Fallopian Tube Neoplasms
4
Carcinoma
4
Astrocytoma
4
Oligodendroglioma
3
Neoplasms, Plasma Cell
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Central Nervous System Neoplasms
3
Carcinoma, Merkel Cell
3
Carcinoma, Hepatocellular
3
Brain Neoplasms
3
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Skin Neoplasms
2
Osteosarcoma
2
Neoplasm Metastasis
2
Interventions
pembrolizumab
10
Cisplatin
9
Cetuximab
9
Paclitaxel
5
Radiotherapy
4
Nivolumab
4
Fluorouracil
4
zalutumumab
3
Docetaxel
3
Taxes
2
Radiotherapy, Intensity-Modulated
2
Pemetrexed
2
Gefitinib
2
Cyclophosphamide
2
Carboplatin
2
temsirolimus
1
sintilimab
1
poly ICLC
1
osimertinib
1
fludarabine phosphate
1
fludarabine
1
enzalutamide
1
durvalumab
1
cobimetinib
1
atezolizumab
1
advexin
1
abemaciclib
1
Vorinostat
1
Sorafenib
1
Risk Factors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Squamous Cell
×
poly ICLC
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled